Prolonged effect of allergen sublingual immunotherapy to grass pollen

Figures & data

Table 1. Efficacy of SLIT during therapy and three-year observation in comparison to placebo.

PATIENTS	AAdSS ± SD
	baseline*	after three years SLIT	differences in adjusted means**	three years of further observation	differences in adjusted means***
SLIT active; n = 38	6.21 ± 1.81	1.38 ± 0.52	−4.83	1.89 ± 0.62	−4.32
SLIT placebo; n = 34	6.13 ± 2.13	6.37 ± 1.29	+ 0.24	5.84 ± 4.02	−0.29
p	NS	0.004	0.0001	0.004	0.0001

Legend: AAdSS – average adjusted symptoms score, *- one-year observation before AIT was started, ** – the differences between AAdSS after three years of AIT and baseline, *** – the differences between AAdSS after the entire observation (six years) and baseline

Table 2. Decrease in the TRS score during observation.

	TCS mean (SE)
	baseline and three years of AIT				follow up after AIT
months of observation	0*	12	24	36	48	60	72
AIT to grass pollen	5.88 (0.7)	2.91 (0.8)	3.14 (0.9)	2.84 (0.6)	3.42 (0.6)	2.96 (0.3)	3.64 (0.6)
placebo	6.01 (0.4)	5.82 (0.6)	6.43 (0.3)	6.11 (0.2)	6.64 (0.5)	5.12 (0.4)	6.44 (0.3)
p	NS	.001	.003	.001	0.01	.001	.002

Legend: * – season of grass pollen before SLIT was started, SLIT- sublingual allergen immunotherapy

Figure 1. Decrease in phleum pratense IgE levels compared in placebo during three years of immunotherapy (I-III and three years of follow up(1-3).

Figure 2. Increase in phleum pratense IgG4 during three years of immunotherapy (I-III and three years of follow up(1-3).

Figure 3. Number of participants assessed for eligibility that completed the study.

Table 3. Characteristics of the patients who completed follow-up.

	active	placebo	p-value
Age (years)	63.18 ± 3.12	64.13 ± 2.92	0.782
Male/female ratio	21/17	18/16	0.423
Duration of rhinitis (years)	11.7 ± 7.5	10.9 ± 8.41	0.145
Number of subject with asthma	3	2	0.89
Number of patients with eczema	2	3	0.223
Number of smokers	4	3	0.631
Number of patients with stable coronary disease	6	7	0.657
Number of patients with arterial hypertension	12	9	0.341
Moderate SAR (according GINA)	18	16	0.022
Severe SAR (according GINA)	23	21	0.116

Legend: SAR – seasonal allergic rhinitis, GINA – Global Initiative for Asthma